RichSource Stem Cells

RichSource Stem Cells was a private U.S. regenerative medicine supplier that marketed perinatal tissue-derived allograft products to physicians, primarily under the RICHGEN brand. Publicly available information indicates the company promoted products composed of amniotic fluid and membrane, Wharton's jelly, and placental tissue for a broad range of conditions. In November 2019, the U.S. Food and Drug Administration issued an untitled letter stating that the company's marketed products appeared to be unapproved biological/drug products and cited non-homologous use claims. The company appears to have operated as a commercial seller of regenerative medicine products rather than as a traditional drug developer with a disclosed clinical pipeline. Corporate listings suggest the legal entity is now inactive.